- Home
- CRTO vs IMCR Comparison
CRTO vs IMCR Comparison
Compare CRTO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRTO | IMCR |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | France | United Kingdom |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.7B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRTO | IMCR |
|---|---|---|
| Price | $20.38 | $36.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $38.67 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 481.4K | 338.1K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.79 | N/A |
| EPS | ★ 3.00 | N/A |
| Revenue | ★ $1,956,800,000.00 | $379,590,000.00 |
| Revenue This Year | N/A | $32.31 |
| Revenue Next Year | $1.42 | $10.50 |
| P/E Ratio | $6.81 | ★ N/A |
| Revenue Growth | 0.53 | ★ 28.11 |
| 52 Week Low | $19.00 | $23.15 |
| 52 Week High | $47.27 | $40.72 |
Technical Indicators
Market Signals| Indicator | CRTO | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 49.05 |
| Support Level | $20.25 | $35.35 |
| Resistance Level | $21.48 | $40.71 |
| Average True Range (ATR) | 0.78 | 1.82 |
| MACD | 0.13 | -0.45 |
| Stochastic Oscillator | 56.65 | 22.55 |
Price Performance
Historical ComparisonAbout CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.